Single-target TKIs include imatinib, dasatinib, gefitinib, etc. Imatinib (STI571, a BCR-ABL TKI) is effective in the treatment of chronic myeloid leukemia (CML). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.